How Long Can You Safely Be on Naltrexone?

There is no fixed upper limit on how long you can take naltrexone. The drug has been prescribed continuously for months to years in clinical trials, and regulatory agencies have not set a maximum treatment duration. Most clinical studies run for six months to a year, but real-world prescribing often extends well beyond that, particularly for alcohol use disorder. The more relevant question is not whether naltrexone becomes dangerous over time but whether it remains useful, whether your liver tolerates it, and how to handle the practical complications that come with long-term opioid-receptor blockade.

What Typical Treatment Timelines Look Like

Naltrexone is approved in two forms: a daily 50 mg oral tablet and a monthly extended-release injection (sold as Vivitrol). Most randomized trials studying either form have run for 12 to 24 weeks. That does not mean treatment should stop at 24 weeks; it means researchers tend to design studies within that window because it is easier to retain participants. In practice, many prescribers recommend staying on naltrexone for at least a year, and some patients continue for several years.

A study tracking extended-release naltrexone over a full year of treatment and then a follow-up year off the drug found that the biggest quality-of-life improvements occurred during the first year of treatment, and those gains held steady during the post-treatment observation period.¹ That finding suggests that a year of treatment can produce durable benefits, though it does not tell us what would happen with two or three years of continuous use since that data is thinner.

For opioid use disorder, adherence data gives us a window into how long people actually stay on the medication. A systematic review of extended-release naltrexone trials found that roughly half of people who started the injections completed six months of treatment. Longer data, from a U.S. study of healthcare professionals, showed adherence rates of about 55% at one year and 37% at two years.² People do take naltrexone for years. Whether they should depends on their individual circumstances and continued benefit.

Liver Safety Over Time

The liver question is the one that keeps coming up, and it is the main reason early prescribing guidelines included cautious language about monitoring. Naltrexone’s original FDA labeling carried a black-box warning about potential hepatotoxicity, based on early studies that used doses several times higher than the current standard. That warning has shaped prescriber anxiety for decades, but more recent evidence has substantially calmed those fears.

A study of 160 patients prescribed naltrexone for alcohol use disorder, nearly two-thirds of whom already had liver disease and about a third of whom had cirrhosis, found that liver enzyme levels actually dropped on average after starting naltrexone. Only three cases of liver enzyme elevation occurred in the entire cohort, and the rate worked out to roughly one to two events per thousand patient-years.³ That is remarkably low, especially considering these patients already had compromised livers. An interesting finding from the same study was that shorter courses of naltrexone (30 days or less) were actually associated with higher hospitalization risk, while longer courses were not, suggesting that stopping early may carry its own dangers.

A separate study specifically examining naltrexone in patients with cirrhosis found similarly reassuring results. Only about 2% of patients had any liver enzyme elevations at all, and when those cases were evaluated, none met the criteria for drug-induced liver injury that was considered even possible, let alone probable.⁴ No deaths or new episodes of liver decompensation were attributed to the drug. The old black-box warning was largely based on doses of 300 mg per day, six times higher than what is prescribed today, and the evidence at standard doses paints a very different picture.

That said, periodic liver function testing is still standard practice, especially in the first few months and for people with pre-existing liver conditions. Your prescriber will likely check liver enzymes before starting and at intervals during treatment. The evidence says this monitoring is prudent, not because problems are common, but because alcohol use disorder itself frequently coexists with liver disease, and it is worth keeping an eye on things.

Does Naltrexone Lose Its Effectiveness Over Time

This is a subtler question than liver safety, and the answer is less reassuring. A meta-analysis examining naltrexone trials for alcohol use disorder over several decades found that the measured effect sizes had decreased over time. The benefit on percent days abstinent declined by a small but consistent amount each year, and the benefit on preventing heavy drinking episodes fell even more steeply.⁵

Before you interpret this as the drug “wearing off” inside your body, the researchers pointed out that this was a trend across different studies conducted in different years, not a finding that any individual patient’s response weakened. The likely explanations are methodological: later trials used stricter designs, included harder-to-treat populations, and had stronger placebo effects. Still, the finding is worth knowing because it tempers the expectation that naltrexone is a magic bullet that works equally well for everyone indefinitely.

At the biological level, there is no strong evidence that your opioid receptors develop tolerance to naltrexone’s blocking effect in the way that they develop tolerance to opioid drugs themselves. Imaging studies show that a single 50 mg oral dose blocks about 95% of mu-opioid receptors within eight hours and maintains over 90% blockade for roughly two days.⁶ The blockade half-life in the brain is estimated at around 72 hours. This pharmacology does not change with long-term use in any documented way.

Mental Health on Long-Term Naltrexone

An early concern about naltrexone was that blocking opioid receptors, which are involved in the brain’s natural reward and pleasure circuits, might cause anhedonia, the clinical term for an inability to feel pleasure. If you are on a medication that blocks reward signals, will you eventually feel flat, joyless, or depressed?

The clinical data is actually encouraging on this point. A study of opioid-dependent patients stabilized on either oral naltrexone or an extended-release naltrexone implant found that depression, anxiety, and anhedonia were all elevated at baseline, before treatment, but dropped to normal ranges within the first one to two months for patients who stayed in treatment and did not relapse.⁷ Another study found that depression scores dropped significantly during extended-release naltrexone treatment in heroin-dependent patients.⁸

The pattern makes sense when you consider what naltrexone is treating. Most people starting the medication are coming off a period of active substance use, which itself causes depression and anxiety. Reducing substance use tends to improve mental health far more than opioid-receptor blockade dampens it. Some patients do report feeling emotionally blunted in the early weeks, but this appears to be uncommon and usually transient. If you notice persistent mood changes on naltrexone, that is worth discussing with your prescriber, but the average trajectory is improvement rather than deterioration.

What Happens If You Need Surgery or Pain Management

This is one of the most important practical considerations for anyone on naltrexone long-term, and it is frequently underappreciated. If you are in an accident, need emergency surgery, or develop a painful condition while on naltrexone, standard opioid painkillers will not work properly because the drug is sitting on the same receptors those painkillers need to activate.

Multiple studies have confirmed that naltrexone increases the amount of opioid medication needed for postoperative pain control, and simply giving more opioids to overcome the blockade is risky because it can lead to respiratory depression once the naltrexone wears off.⁹ The recommended approach is to use non-opioid alternatives: regional nerve blocks with local anesthetics, ketamine, anti-inflammatory drugs, and other multimodal pain strategies.

If you are on oral naltrexone and have a planned surgery, your prescriber may advise stopping the medication several days beforehand so that the receptor blockade clears. With the monthly injection, you do not have that option since the drug releases slowly from the injection site over about 30 days. This means anyone on extended-release naltrexone who faces an unexpected medical emergency needs to make sure the medical team knows about the medication. Wearing a medical alert bracelet or card is a practical step that can genuinely matter in an emergency room scenario.

The Low-Dose Naltrexone Question

Low-dose naltrexone, typically 1 to 5 mg per day, is a different animal from standard-dose naltrexone for addiction. It is prescribed off-label for chronic pain conditions like fibromyalgia, autoimmune diseases, and more recently has been explored for long COVID. At these low doses, the mechanism is thought to be anti-inflammatory rather than receptor-blocking, and the safety profile looks different as well.

People often take LDN for years, and the available trial data on side effects is quite mild. Researchers studying LDN for chronic pain reported no severe adverse events across their trials, no withdrawal symptoms when treatment was stopped, and no interference with common medications.¹⁰ The caveat, acknowledged by the researchers themselves, is that the total number of participants in all LDN trials combined remains small, so rare adverse events could still be lurking undetected.

A 12-month randomized, double-blind trial of LDN in women with fibromyalgia provides some of the best long-term safety data available. Adverse events were reported at similar rates in both the LDN group and the placebo group, about 69% versus 72%, and the vast majority of those events were mild. No serious adverse events were attributed to the treatment.¹¹ The most common complaints in the LDN group were nervous system symptoms like vivid dreams and mild headaches, and these usually appeared early and faded. A smaller study of LDN for long COVID found that about 5% of participants discontinued due to side effects, mainly diarrhea and fatigue.¹²

The practical upshot for LDN users is that the side-effect profile appears favorable enough for extended use, but the evidence base is still catching up to the enthusiasm. If you are using LDN for an off-label condition and tolerating it well, the existing data does not suggest a ticking clock of accumulating toxicity. The bigger question is whether the benefit is real, which varies substantially by condition and by individual.

Naltrexone During Pregnancy

Pregnancy introduces a completely different risk calculus. Naltrexone is not the preferred treatment for opioid use disorder during pregnancy: buprenorphine holds that position, with methadone as the other established option. But some women become pregnant while already on naltrexone, and a growing body of case data is filling in the safety picture.

A case series of individuals treated with naltrexone during pregnancy for opioid or alcohol use disorder found no reported fetal anomalies, and none of the infants developed neonatal opioid withdrawal syndrome.¹³ A pilot study comparing naltrexone-maintained pregnancies to buprenorphine-maintained pregnancies found comparable outcomes, with the naltrexone group showing no opioid misuse and shorter infant hospital stays.¹⁴

However, a scoping review that pulled together multiple studies introduced some caution. While the largest study of 121 pregnant patients found that naltrexone-exposed neonates had lower rates of withdrawal syndrome compared to those exposed to methadone or buprenorphine, other studies flagged signals that naltrexone-exposed babies tended to be smaller and had higher rates of certain urogenital birth defects. Those children also showed elevated rates of hospital visits and ear infections in early childhood.¹⁵ These findings come from small, observational studies where the comparison groups are imperfect, so it is hard to separate the drug’s effects from the effects of the underlying substance use disorder. The current medical consensus is that if you become pregnant on naltrexone, the decision about whether to continue should be made with your doctor on a case-by-case basis.

Drug Interactions and Opioid Medications

Naltrexone has relatively few drug-drug interactions compared to many other medications. A comprehensive review of interactions among alcohol use disorder pharmacotherapies found naltrexone to be relatively safe for pharmacological interactions, with one critical exception: combining it with any opioid medication will precipitate withdrawal in someone who is opioid-dependent, and will block the effect of opioids in anyone.¹⁶

This matters beyond the obvious addiction context. Opioid-containing cough suppressants, certain anti-diarrheal medications like loperamide at high doses, and opioid-based anesthetics used during procedures are all affected. If you are prescribed naltrexone, you should let every healthcare provider who treats you know about it, including dentists and urgent care physicians. The interaction is not a toxic reaction; it is a pharmacological inevitability. The drug’s whole purpose is to block opioid receptors, and it does so indiscriminately.

The Cost Question for Long-Term Use

Duration decisions are not purely medical. The extended-release injection, which is the form with better adherence, is expensive. A cost-effectiveness analysis of extended-release naltrexone for people with opioid use disorder leaving the criminal justice system found that while the drug increased both quality-adjusted life-years and abstinence, it did not meet standard cost-effectiveness thresholds at 25 weeks due to the high price of the injection. The picture improved with longer treatment: at 78 weeks, the cost per quality-adjusted life-year dropped to about $76,000, approaching the commonly used threshold of $100,000.¹⁷

Generic oral naltrexone, by contrast, is relatively cheap and is covered by most insurance plans. If you are on the oral form and tolerating it, cost is unlikely to be the limiting factor. For the injection, though, the economics tilt toward longer treatment: the upfront investment makes more sense the longer you stay on it, because the benefits accumulate while the monthly cost stays flat. Insurance coverage varies, and prior authorization requirements can create gaps in treatment that undermine adherence. If you are considering the injection, sorting out the insurance logistics early can save a lot of frustration down the line.

When People Choose to Stop

There is no standard protocol for when to discontinue naltrexone. In alcohol use disorder treatment, some prescribers suggest a minimum of three to six months, with many recommending at least a year. For opioid use disorder, longer is generally considered better because the risk of relapse and fatal overdose after stopping can be substantial, particularly in the first weeks when tolerance has been lost but the protective blockade is gone.

Naltrexone itself does not cause physical dependence. You will not experience withdrawal symptoms if you stop taking it, which is a meaningful advantage over methadone and buprenorphine for opioid use disorder. The danger is not in stopping the drug; it is in what happens next. If you have been on naltrexone for months, your opioid tolerance has dropped to near zero. A dose of heroin or prescription opioids that you once handled easily could now be lethal. This risk window after discontinuation is well recognized in the clinical literature and is the strongest argument for not stopping abruptly or without a plan.

The decision to taper or stop should be a conversation with your prescriber, ideally timed around a period of stability rather than a moment of crisis. Some people use naltrexone as a bridge: long enough to build new habits, establish therapy, and stabilize their living situation, and then gradually step away from the medication with a safety net in place. Others treat it as an indefinite maintenance therapy, no different from a blood pressure medication that they plan to take for life. Neither approach is inherently right or wrong. The available evidence supports both strategies depending on the person and the condition being treated.